Ethical issues in growth hormone therapy

Area of Science:

• Pediatric Endocrinology
• Medical Ethics
• Child Health Policy

Background:

• Pediatricians grapple with ethical dilemmas regarding growth hormone (GH) therapy for short children lacking classic GH deficiency criteria.
• Biological health norms are insufficient for evaluating GH therapy due to the complex relationship between stature, GH secretion, health, and disease.

Purpose of the Study:

• To evaluate the ethical considerations of GH therapy for short children without documented GH deficiency.
• To compare GH therapy for short normal children with accepted treatments for other non-life-threatening pediatric conditions.

Main Methods:

• Analysis of clinical and ethical dilemmas surrounding GH therapy.
• Comparison of GH therapy with established pediatric care models (well-child care, cosmetic therapy, psychological treatment, chronic condition management).

Main Results:

• GH therapy for short children without documented deficiency poses ethical concerns due to treatment burdens, uncertain long-term outcomes, and unclear endpoints.
• Current pediatric ethical norms do not support routine GH therapy for these children.

Conclusions:

• Routine GH therapy for short children without documented GH deficiency falls outside current pediatric ethical standards.
• Such therapy should be administered within comprehensive clinical research protocols to address ethical and safety concerns.